Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.84

€0.84

2.940%
0.024
2.940%
€8.84
 
14:53 / Tradegate WKN: A2PHD4 / Symbol: IMUX / Name: Immunic / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Immunic Inc. Stock

Immunic Inc. gained 2.940% today.
We see a rather positive sentiment for Immunic Inc. with 20 Buy predictions and 1 Sell predictions.
Based on the current price of 0.84 € the target price of 8 € shows a potential of 852.38% for Immunic Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Immunic Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Immunic Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Immunic Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Immunic Inc. 2.940% 8.945% 14.286% -43.017% -19.288% -76.545% -94.932%
NanoViricides Inc. -0.830% 0.000% 2.586% -8.462% -20.667% -32.116% -63.272%
Actinium Pharmaceuticals Inc. 1.840% -1.805% -6.336% -15.894% 18.158% -81.927% -83.505%
Ocuphire Pharma Inc. 8.370% 19.077% 51.172% 32.534% 39.459% -24.525% -

Comments

Prediction Buy
Perf. (%) -0.47%
Target price 2.559
Change
Ends at 29.09.26

Immunic (NASDAQ:IMUX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $3.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 9.09%
Target price 8.570
Change
Ends at 26.09.26

Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 15.07%
Target price 8.516
Change
Ends at 25.09.26

Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Ratings data for IMUX provided by MarketBeat
Show more

News

EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis